Literature DB >> 21552284

Prostate cancer: an emerging threat to the health of aging men in Asia.

Ling Zhang1, Bao-Xue Yang, Hai-Tao Zhang, Jin-Guo Wang, Hong-Liang Wang, Xue-Jian Zhao.   

Abstract

The aim of this study was to determine and examine the possible reasons for the difference in prostate cancer incidence between Asian men and North American men by literature review. Data regarding cancer incidence and mortality were obtained from the database of the International Agency for Research on Cancer (IARC). A literature review was conducted by studying related articles published in peer-reviewed journals such as the The New England Journal of Medicine, Journal of Clinical Oncology, A Cancer Journal for Clinicians and Asian Journal of Andrology. To evaluate the early diagnosis and survival rates, the mortality-to-incidence rate ratio (MR/IR) was calculated from the IARC data. By comparing prostate cancer data between Asian men and North American men, we found that differences in the incidence rate and MR/IR could be attributed largely to a lack of annual prostate cancer screening with serum prostate-specific antigen (PSA) in most Asian countries. It is likely that PSA screening also contributes significantly to the differences in prostate cancer mortality rates. Prostate cancer has the highest incidence rate among five common malignancies in Asian Americans. However, the MR/IR ratio of prostate cancer is the lowest among cancers. These data seem to further support the usefulness of PSA screening, even though the percentage of low risk cancers is greater in prostate cancer than in other cancers. The low incidence rate of prostate cancer does not reflect the actual statistics of this disease in Asia. The data from limited institutions in many Asian countries seem to bias the true incidence and mortality rates. To improve this situation, incorporating PSA screening for prostate cancer, as well as constructing a nationwide cancer registration system, will be helpful.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21552284      PMCID: PMC3739604          DOI: 10.1038/aja.2010.126

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  21 in total

1.  Geriatric oncology: an overview of progresses and challenges.

Authors:  Martine Extermann
Journal:  Cancer Res Treat       Date:  2010-06-30       Impact factor: 4.679

2.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

3.  Mass screening of prostate cancer in Changchun City of China.

Authors:  Xiaomeng Li; Itiro Tsuji; Masaaki Kuwahara; Haifeng Zhang; Hongliang Wang; Ling Zhang; Guoyi Ji; Xuejian Zhao
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 4.  Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening.

Authors:  Robert A Smith; Vilma Cokkinides; Durado Brooks; Debbie Saslow; Otis W Brawley
Journal:  CA Cancer J Clin       Date:  2010 Mar-Apr       Impact factor: 508.702

5.  Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen.

Authors:  Hong-Wen Gao; Yu-Lin Li; Shan Wu; Yi-Shu Wang; Hai-Feng Zhang; Yu-Zhuo Pan; Ling Zhang; Hiroo Tateno; Ikuro Sato; Masaaki Kuwahara; Xue-Jian Zhao
Journal:  Asian J Androl       Date:  2005-06       Impact factor: 3.285

6.  Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue.

Authors:  Leonard S Marks; Munekado Kojima; Angelo Demarzo; David Heber; David G Bostwick; Junqi Qian; Frederick J Dorey; Robert W Veltri; James L Mohler; Alan W Partin
Journal:  Urology       Date:  2004-10       Impact factor: 2.649

7.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

8.  Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey.

Authors:  Louie E Ross; Zahava Berkowitz; Donatus U Ekwueme
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

Review 9.  Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China.

Authors:  Ling Zhang; Shan Wu; Li-Rong Guo; Xue-Jian Zhao
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

10.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

Authors:  Thomas A Stamey; Mitchell Caldwell; John E McNeal; Rosalie Nolley; Marci Hemenez; Joshua Downs
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

View more
  36 in total

1.  Scientific publications in urology and nephrology journals from China: A 10-year analysis.

Authors:  Xiaomei Zhou; Changyong Xing; Lei Xin; Hongzhen Hu; Liping Li; Jingchuan Fang; Zhiyong Liu
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

2.  Analysis of circulating regulatory T cells (CD4+CD25+CD127-) after cryosurgery in prostate cancer.

Authors:  Tong-Guo Si; Jun-Ping Wang; Zhi Guo
Journal:  Asian J Androl       Date:  2013-06-03       Impact factor: 3.285

3.  Clinical significance of CUL4A in human prostate cancer.

Authors:  Gang Liu; Zengjun Zhu; Fang Lang; Bao Li; Dianjun Gao
Journal:  Tumour Biol       Date:  2015-06-03

4.  Prostate cancer risk and aggressiveness associated with the CYP1B1 4326C/G (Leu432Val) polymorphism: a meta-analysis of 2788 cases and 2968 controls.

Authors:  Jie Yang; Dong-Liang Xu; Qiang Lu; Zhi-Jian Han; Jun Tao; Pei Lu; Chao Wang; Xiao-Ke Di; Min Gu
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

5.  ChIP-seq analysis of androgen receptor in LNCaP cell line.

Authors:  Sifeng Tao; Haifei He; Qiang Chen
Journal:  Mol Biol Rep       Date:  2014-07-02       Impact factor: 2.316

Review 6.  Dietary antioxidants and prostate cancer: a review.

Authors:  Terrence M Vance; Joseph Su; Elizabeth T H Fontham; Sung I Koo; Ock K Chun
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

7.  Pin1 promotes prostate cancer cell proliferation and migration through activation of Wnt/β-catenin signaling.

Authors:  Z Zhu; H Zhang; F Lang; G Liu; D Gao; B Li; Y Liu
Journal:  Clin Transl Oncol       Date:  2015-10-26       Impact factor: 3.405

8.  Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.

Authors:  Wei Hu; Rui-Rui Zheng; Hui-Xia Cui; Dan Yue; Yong Wang; You-Hong Jiang
Journal:  Asian J Androl       Date:  2012-08-20       Impact factor: 3.285

9.  The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis.

Authors:  Jie Yang; Wen Gao; Ning-Hong Song; Wei Wang; Jie-Xiu Zhang; Pei Lu; Li-Xin Hua; Min Gu
Journal:  Asian J Androl       Date:  2012-08-20       Impact factor: 3.285

10.  The likelihood of having a serum PSA level of ≥2.5 or ≥4.0 ng ml(-1) according to obesity in a screened Korean population.

Authors:  Won Jae Yang
Journal:  Asian J Androl       Date:  2013-08-05       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.